Efficacy and safety of continuing sitagliptin when initiating insulin therapy in subjects with type 2 diabetes

被引：0
|
作者：
Roussel, R. [1 ]
Duran-Garcia, S. [2 ]
Zhang, Y. [3 ]
Shah, S. [3 ]
Darmiento, C. [3 ]
Shankar, R. R. [3 ]
O'Neill, E. A. [3 ]
Golm, G. T. [3 ]
Lam, R. L. H. [3 ]
Gantz, I. [3 ]
Kaufman, K. D. [3 ]
Engel, S. S. [3 ]
机构：
[1] Grp Hosp Bichat, Paris, France
[2] Valme Univ Hosp, Med Sch, Seville, Spain
[3] Merck & Co Inc, Kenilworth, NJ USA
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
770
引用
收藏
页码：S378 / S378
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of sitagliptin over 18 weeks in patients with type 2 diabetes
    Raz, I.
    Hanefeld, M.
    Xu, L.
    Caria, C.
    Meehan, A. G.
    Williams-Herman, D.
    Khatami, H.
    DIABETOLOGIA, 2006, 49 : 481 - 481
  • [42] Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes
    Harashima, S-I.
    Ogura, M.
    Tanaka, D.
    Fukushima, T.
    Wang, Y.
    Koizumi, T.
    Aono, M.
    Murata, Y.
    Seike, M.
    Inagaki, N.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (05) : 465 - 476
  • [43] The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes
    Beljic-Zivkovic, Teodora
    Marjanovic-Petkovic, Milica
    Vuksanovic, Miljanka
    Soldatovic, Ivan
    Kanlic, Dobrila
    Topalov, Drina
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2016, 144 (9-10) : 497 - 502
  • [44] Comparison of Efficacy and Safety of Sitagliptin and Glimepiride in Treatment of Type 2 Diabetes Mellitus
    Hussain, Shabir
    Mustafa, Amjad
    Mumtaz, Arif
    Shaheen, Ghazala
    Qaiser, Fawad
    Soban, Mohammad
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (10): : 2800 - 2803
  • [45] Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
    Aschner, P.
    Katzeff, H. L.
    Guo, H.
    Sunga, S.
    Williams-Herman, D.
    Kaufman, K. D.
    Goldstein, B. J.
    DIABETES OBESITY & METABOLISM, 2010, 12 (03): : 252 - 261
  • [46] Initiating basal insulin therapy in patients with type 2 diabetes mellitus
    Stoneking, K
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (05) : 510 - 518
  • [47] Current barriers to initiating insulin therapy in individuals with type 2 diabetes
    Sanz-Pastor, Alba Galdon
    Enriquez, Alicia Justel
    Bao, Ana Sanchez
    Ampudia-Blasco, Francisco Javier
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [48] The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy
    Fouqueray, Pascale
    Pirags, Valdis
    Diamant, Michaela
    Schernthaner, Guntram
    Lebovitz, Harold E.
    Inzucchi, Silvio E.
    Bailey, Clifford J.
    DIABETES CARE, 2014, 37 (07) : 1924 - 1930
  • [49] Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
    Williams-Herman, D.
    Johnson, J.
    Teng, R.
    Golm, G.
    Kaufman, K. D.
    Goldstein, B. J.
    Amatruda, J. M.
    DIABETES OBESITY & METABOLISM, 2010, 12 (05): : 442 - 451
  • [50] Continuation vs. Discontinuation of Insulin Secretagogues When Initiating Insulin in Type 2 Diabetes
    Swinnen, Sanne G.
    Dain, Marie-Paule
    Mauricio, Didac
    Devries, J. Hans
    Hoekstra, Joost B.
    Holleman, Frits
    DIABETES, 2010, 59 : A10 - A10
12345